Related Experiment Video

Updated: Aug 14, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Targeted therapy against Bcl-2-related proteins in breast cancer cells

Manabu Emi1, Ryungsa Kim, Kazuaki Tanabe

  • 1Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Breast Cancer Research : BCR
|November 11, 2005
PubMed
Abstract

Insights

Targeting Bcl-2 and Bcl-xL proteins with antisense oligodeoxynucleotides (AS ODNs) can overcome chemotherapy resistance in breast cancer. This approach enhances the effectiveness of common chemotherapeutic agents against cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Bcl-2 and Bcl-xL proteins promote cancer cell survival by inhibiting apoptosis.
  • This resistance mechanism reduces the efficacy of conventional chemotherapy.
  • Targeting these proteins offers a strategy for overcoming treatment resistance.

Purpose of the Study:

  • To investigate the role of Bcl-2 and Bcl-xL in breast cancer chemosensitivity.
  • To evaluate the potential of antisense oligodeoxynucleotides (AS ODNs) targeting Bcl-2 and Bcl-xL for enhancing chemotherapy.
  • To develop targeted therapies for breast cancer.

Main Methods:

  • Utilized four human breast cancer cell lines for in vitro and in vivo studies.
  • Administered antisense (AS) Bcl-2 and AS Bcl-xL phosphorothioate oligodeoxynucleotides (ODNs).
  • Assessed chemosensitivity using MTT assays and antitumor effects via xenograft transplantation in athymic mice.

Main Results:

  • AS Bcl-2 and AS Bcl-xL ODNs effectively reduced target protein expression.
  • AS Bcl-2 significantly enhanced chemosensitivity to doxorubicin, mitomycin C, paclitaxel, and docetaxel.
  • AS Bcl-xL also improved chemosensitivity, though to a lesser extent than AS Bcl-2, with associated changes in apoptosis markers.

Conclusions:

  • Bcl-2 is a key determinant of chemosensitivity in breast cancer.
  • Targeted therapy using AS ODNs against Bcl-2 holds promise for improving chemotherapy outcomes.
  • This strategy may enhance the effectiveness of chemotherapy in breast cancer patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...